Beactica Extends Fragment-Based Discovery Research Services Agreement
|| Print ||
|Wednesday, 28 November 2012 09:00 (UTC + 1)|
Uppsala, Sweden, November 28, 2012 / B3C newswire / - Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the research services agreement, Beactica will use its proprietary drug discovery platform Sprint™ to identify novel allosteric modulators targeting undisclosed central nervous system (CNS) proteins of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.
“We are pleased to extend our collaboration with Janssen and look forward to further supporting their efforts to discover innovative medicines” said Beactica CEO, Dr Per Källblad. “The extension of our relationship testifies to the ability of our Sprint™ platform to generate novel, high-quality medicinal chemistry starting points against challenging drug targets”.
Beactica initiated their first research services project with Janssen in early 2011.